Literature DB >> 17805938

Local excision for ypT2 rectal cancer--much ado about something.

Rodrigo O Perez1, Angelita Habr-Gama, Igor Proscurshim, Fábio G Campos, Desiderio Kiss, Joaquim Gama-Rodrigues, Ivan Cecconello.   

Abstract

BACKGROUND: The role of local excision for pT2 distal rectal cancer has been challenged because of the observation of high rates of lymph node metastases and local failure. However, neoadjuvant chemoradiation therapy (CRT) has led to increased local disease control and significant tumor downstaging, possibly decreasing rates of lymph node metastases. In this setting, a possible role for local excision of ypT2 has been suggested.
METHODS: A total of 401 patients with distal rectal cancer underwent neoadjuvant CRT. Tumor response assessment was performed after at least 8 weeks from CRT completion. One hundred and twelve patients with complete clinical response were not immediately operated on and were excluded from the study, and 289 patients with incomplete clinical response were managed by radical surgery. Patients with final pathological stage ypT2 were analyzed to determine the risk of unfavorable pathological features that could represent unacceptable risk for local failure after local excision.
RESULTS: Eighty-eight (30%) patients had ypT2 rectal cancer. Final ypT status was not associated with pretreatment radiological staging (p = 0.62). ypT status was significantly associated with the risk of lymph node metastases, risk of perineural and vascular invasion, and recurrence (p = 0.001). Lymph node metastases were present in 19% of patients with ypT2 rectal cancer. The risk of lymph node metastases in ypT2 was associated with the presence of perineural invasion (47% vs 4%; p = <0.001), vascular invasion (59% vs 6%; p < 0.001), and decreased mean interval CRT surgery (12 vs 18 weeks; p < 0.001), but not with mean tumor size (3.2 vs 3.1 cm; p = 0.8). Disease-free and overall survival rates were significantly better for patients with ypT2N0 (p = 0.02 and 0.006, respectively). Fifty-five (63%) patients with ypT2 had at least one unfavorable pathological feature for local excision (lymph node metastases, vascular or perineural invasion, mucinous type or tumor size >3 cm).
CONCLUSION: Lymph node metastases were present in 19% of patients with ypT2 and were significantly associated with poor overall and disease-free survival rates. The risk of lymph node metastases could not be predicted by radiological staging or tumor size. Radical surgery should be considered the standard treatment option for ypT2 rectal cancer after CRT.

Entities:  

Mesh:

Year:  2007        PMID: 17805938     DOI: 10.1007/s11605-007-0271-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  Local excision of rectal cancer revisited: ACOSOG protocol Z6041.

Authors:  David M Ota; Heidi Nelson
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

2.  Low rectal cancer: a call for a change of approach in abdominoperineal resection.

Authors:  Iris D Nagtegaal; Cornelius J H van de Velde; Corrie A M Marijnen; Jan H J M van Krieken; Philip Quirke
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

3.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

4.  Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy.

Authors:  A Habr-Gama
Journal:  Colorectal Dis       Date:  2006-09       Impact factor: 3.788

5.  Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis.

Authors:  Huann-Sheng Wang; Wen-Yih Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Shung-Haur Yang; Shih-Ching Chang; Jen-Kou Lin
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

6.  Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service.

Authors:  David B Chessin; Warren Enker; Alfred M Cohen; Philip B Paty; Martin R Weiser; Leonard Saltz; Bruce D Minsky; W Douglas Wong; Jose G Guillem
Journal:  J Am Coll Surg       Date:  2005-06       Impact factor: 6.113

7.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

8.  Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Salvatore Pucciarelli; Carlo Capirci; Urso Emanuele; Paola Toppan; Maria Luisa Friso; Gian Maria Pennelli; Giovanni Crepaldi; Lara Pasetto; Donato Nitti; Mario Lise
Journal:  Ann Surg Oncol       Date:  2005-02-04       Impact factor: 5.344

9.  Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.

Authors:  Angelita Habr-Gama; Rodrigo Oliva Perez; Wladimir Nadalin; Sérgio Carlos Nahas; Ulysses Ribeiro; Afonso Henrique Silva E Sousa; Fábio Guilherme Campos; Desidério Roberto Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2005-01       Impact factor: 3.452

10.  Immediate radical resection after local excision of rectal cancer: an oncologic compromise?

Authors:  Dieter Hahnloser; Bruce G Wolff; David W Larson; Jennifer Ping; Santhat Nivatvongs
Journal:  Dis Colon Rectum       Date:  2005-03       Impact factor: 4.585

View more
  12 in total

1.  Transanal Endoscopic Microsurgery with or without Completion Total Mesorectal Excision for T2 and T3 Rectal Carcinoma.

Authors:  Jeroen W A Leijtens; Thomas W A Koedam; Wernard A A Borstlap; Monique Maas; Pascal G Doornebosch; Tom M Karsten; Eric J Derksen; Laurents P S Stassen; Camiel Rosman; Eelco J R de Graaf; André J A Bremers; Jeroen Heemskerk; Geerard L Beets; Jurriaan B Tuynman; Kevin L J Rademakers
Journal:  Dig Surg       Date:  2018-05-23       Impact factor: 2.588

Review 2.  Local Excision and Endoscopic Resections for Early Rectal Cancer.

Authors:  Guilherme Pagin São Julião; Juan Pablo Celentano; Flavia Andrea Alexandre; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

3.  [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].

Authors:  T Sprenger; H Rothe; T Beissbarth; L-C Conradi; A Kauffels; K Homayounfar; C L Behnes; C Rödel; T Liersch; M Ghadimi
Journal:  Chirurg       Date:  2016-07       Impact factor: 0.955

4.  Transanal minimally invasive surgery (TAMIS) using a new disposable device: our initial experience.

Authors:  G Sevá-Pereira; V L Trombeta; L G Capochim Romagnolo
Journal:  Tech Coloproctol       Date:  2013-06-06       Impact factor: 3.781

Review 5.  Transanal Local Excision of Rectal Cancer after Neoadjuvant Chemoradiation: Is There a Place for It or Should Be Avoided at All Costs?

Authors:  Rodrigo Oliva Perez; Guilherme Pagin São Julião; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2022-02-28

6.  Short- and long-term outcomes in ypT2 rectal cancer patients after neoadjuvant therapy and local excision: a multicentre observational study.

Authors:  Roberto Peltrini; Simone Castiglioni; Nicola Imperatore; Monica Ortenzi; Daniela Rega; Valentina Romeo; Valerio Caracino; Edoardo Liberatore; Massimo Basti; Emanuele Santoro; Umberto Bracale; Paolo Delrio; Felice Mucilli; Mario Guerrieri; Francesco Corcione
Journal:  Tech Coloproctol       Date:  2022-10-14       Impact factor: 3.699

Review 7.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 8.  Treatment of locally advanced rectal cancer: controversies and questions.

Authors:  Atthaphorn Trakarnsanga; Suthinee Ithimakin; Martin R Weiser
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

9.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

Review 10.  Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges.

Authors:  Patrick E Young; Craig M Womeldorph; Eric K Johnson; Justin A Maykel; Bjorn Brucher; Alex Stojadinovic; Itzhak Avital; Aviram Nissan; Scott R Steele
Journal:  J Cancer       Date:  2014-03-15       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.